ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURE
ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURE
批准号:
8400879
负责人:
IGOR R EFIMOV
金额:
$50.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-15 至 2016-07-31
关键词:
Action PotentialsAdherens JunctionAdrenergic AgentsAmericanAnatomyAngiotensinsAnimal ModelAnimalsAnisotropyArrhythmiaBiomedical ResearchCalciumCanis familiarisCardiacCardiomyopathiesCaviaCell LineCellsClinicalClinical TrialsCommunitiesCouplingDataDiseaseEmployee StrikesEtiologyFailureFunctional disorderGap JunctionsGenesGiftsHeartHeart TransplantationHeart failureHeterogeneityHomo sapiensHumanIn VitroInvestigationIon ChannelKnowledgeLaboratoriesLeadLifeLinkMapsMediatingMediator of activation proteinMethodologyModelingMolecularMolecular Biology TechniquesMolecular GeneticsMorbidity - disease rateMusMyocardiumNa(+)-K(+)-Exchanging ATPaseOperative Surgical ProceduresOpticsOrganOryctolagus cuniculusPathologicPathologic ProcessesPatientsPhysiologicalPhysiologyPreparationPropertyProteinsPumpRattusResearchSafetySignal TransductionStressSudden DeathSymptomsTestingTherapeuticTissue DonorsTissuesTranslational ResearchTranslationsTransplantationTreatment EfficacyValidationVentricularadrenergicbaseheart rhythmimplantable devicemortalityprogramsreceptorsudden cardiac deaththerapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Heart failure (HF) is the leading cause of mortality and morbidity, which afflicts 5.7 million Americans. HF management includes surgery, implantable device and pharmacological therapy targeting angiotensin and adrenergic signaling. Numerous animal models of heart failure have been generated and studied for decades in effort to identify therapeutic targets for treatment of human HF patients. However, it is becoming increasingly evident that this strategy has yielded limited therapeutic options for the treatment o HF. Significant genetic, molecular, cellular, anatomical, and systemic differences among species are likely to be responsible for failure of translation from cell lines and animal models t humans. Cardiac rhythm disorders are striking examples of such translational failure. Despite deep knowledge of the biophysical properties of numerous ion channels, pumps, and exchangers gained over half a century of research conducted at huge expense, current pharmacological therapies used to treat arrhythmias are nonspecific and often ineffective. The main reason for this failure is the complexity of human cardiac physiology at the molecular, cellular and tissue levels. It is paradoxical, but we know much more about ion channels and action potentials in the mouse, rat, guinea pig, rabbit, and canine as compared to our own species - Homo sapiens. We have recently developed a program, which allows investigation of the mechanisms of arrhythmogenic remodeling in live human hearts in vitro. In this project we will investigate a number of mechanistic hypothesis linking HF and arrhythmia in live cardiac tissue from donors and patients with HF. In summary, we will develop, refine and extend experimental methodology, which is currently applied only to animal cardiac preparations in basic physiology laboratories, to deepen our understanding of human cardiac pathophysiology. This approach will modify and enhance the currently dominant translational paradigm and provide new important directions of research, which will stimulate and reinvigorate a biomedical research community that has ignored human physiology and thus delayed effective translation of needed therapies for HF and sudden cardiac death.
PUBLIC HEALTH RELEVANCE: Our project aims to bridge the gap between fundamental discoveries in animal models of human heart failure and its validation in clinical trials. We will
develop methodology to produce critically important new physiological knowledge about the cardiac function of the human species, using explanted hearts of transplantation patients and donor hearts rejected from transplantation. These precious gifts of live human hearts will yield critically important new knowledge about pathological processes occurring during heart failure in humans that lead to sudden cardiac death of hundreds of thousands of patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of electromechanical monitoring of engineered heart tissues
-
批准号:10673513
-
项目类别:
-
资助金额:$46.67万
-
财政年份:2023
-
负责人:IGOR R EFIMOV
-
依托单位:
Reagentless Sensor Technologies For Continuous Monitoring of Heart Failure Biomarkers
-
批准号:10636089
-
项目类别:
-
资助金额:$76.97万
-
财政年份:2023
-
负责人:IGOR R EFIMOV
-
依托单位:
Graphene optoelectronic biointerfaces for enabling optical cardiac pacemaking
-
批准号:10651242
-
项目类别:
-
资助金额:$10.63万
-
财政年份:2020
-
负责人:IGOR R EFIMOV
-
依托单位:
Graphene optoelectronic biointerfaces for enabling optical cardiac pacemaking
-
批准号:10163905
-
项目类别:
-
资助金额:$12.59万
-
财政年份:2020
-
负责人:IGOR R EFIMOV
-
依托单位:
High-Definition Conformal Electronics for VT/VF
-
批准号:10661291
-
项目类别:
-
资助金额:$62.33万
-
财政年份:2019
-
负责人:IGOR R EFIMOV
-
依托单位:
Comprehensive Structural and Functional Mapping of the Mammalian Cardiac Nervous System
-
批准号:10428804
-
项目类别:
-
资助金额:$243.41万
-
财政年份:2016
-
负责人:IGOR R EFIMOV
-
依托单位:
Exploration of Arrhythmogenic Triggers and Substrates in Heart Failure
-
批准号:9198047
-
项目类别:
-
资助金额:$69.4万
-
财政年份:2016
-
负责人:IGOR R EFIMOV
-
依托单位:
Comprehensive Structural and Functional Mapping of the Mammalian Cardiac Nervous System
-
批准号:10202966
-
项目类别:
-
资助金额:$248.64万
-
财政年份:2016
-
负责人:IGOR R EFIMOV
-
依托单位:
Near-infrared optogenetic control of the human heart
-
批准号:9357602
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2016
-
负责人:IGOR R EFIMOV
-
依托单位:
Exploration of Arrhythmogenic Triggers and Substrates in Heart Failure
-
批准号:9392927
-
项目类别:
-
资助金额:$66.41万
-
财政年份:2016
-
负责人:IGOR R EFIMOV
-
依托单位:
Low Energy Defibrillation
-
批准号:8533723
-
项目类别:
-
资助金额:$57.48万
-
财政年份:2013
-
负责人:IGOR R EFIMOV
-
依托单位:
Low Energy Defibrillation
-
批准号:8665479
-
项目类别:
-
资助金额:$53.48万
-
财政年份:2013
-
负责人:IGOR R EFIMOV
-
依托单位:
Low Energy Defibrillation
-
批准号:9014977
-
项目类别:
-
资助金额:$48.68万
-
财政年份:2013
-
负责人:IGOR R EFIMOV
-
依托单位:
ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURE
-
批准号:8702227
-
项目类别:
-
资助金额:$49.63万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURE
-
批准号:8529268
-
项目类别:
-
资助金额:$52.12万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURE
-
批准号:8676188
-
项目类别:
-
资助金额:$9.63万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
OPTO-ELECTRIC MAPPING OF ACTION POTENTIALS
-
批准号:8308850
-
项目类别:
-
资助金额:$24.41万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
OPTO-ELECTRIC MAPPING OF ACTION POTENTIALS
-
批准号:8458534
-
项目类别:
-
资助金额:$18.39万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURE
-
批准号:9032162
-
项目类别:
-
资助金额:$50.16万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
Low energy ventricular defibrillator
-
批准号:8315768
-
项目类别:
-
资助金额:$25.07万
-
财政年份:2012
-
负责人:IGOR R EFIMOV
-
依托单位:
海外基金